Alprazolam

Xanax

Benzodiazepine • Short-acting benzodiazepine

Premium

CNS Depressant

Half-life

6-12 hours

Protein Binding

80%

Metabolized By

CYP3A4

External

Drugs.com

Boxed warning

Opioid co-use risks CNS depression/death
Dependence and withdrawal

Clinical alerts

Boxed warning

2 boxed warnings

CNS depressant

Additive sedation with other CNS depressants and alcohol

Mechanism of action

Enhances GABA-A receptor activity, producing anxiolytic/sedative effects

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Stereotypical Prolonged Seizures
·Healthy Participants
·Opioid Abuse
·Benzodiazepine Abuse
·Polysubstance Abuse

Interactions

3 curated · 3 major or contraindicated · select a row for management

Interacting drug	Severity	Effect
heroin	contraindicated	Profound respiratory depression, fatal overdose risk dramatically increased
oxycodone	contraindicated	LIFE-THREATENING respiratory depression, profound sedation, coma, and death.
rifampicin	major	Marked reduction in anxiolytic effect; risk of benzodiazepine withdrawal in chronic users.

Common adverse effects

Sedation
Dizziness
Memory impairment
Dependence

Food, alcohol & herbal

Food

Grapefruit may increase levels

Alcohol · major

Profound CNS and respiratory depression. CONTRAINDICATED.

Herbal

Kava (major) — Additive CNS depression and hepatotoxicity
Valerian (moderate) — Additive sedation

Pharmacokinetics

Half-life: 6-12 hours
Protein binding: 80%
Metabolised by: CYP3A4

Pregnancy & lactation

Not recorded for Alprazolam. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, curated interaction pairs.

Not a substitute for clinical judgement

Alprazolam

Xanax

Benzodiazepine • Short-acting benzodiazepine

Premium

CNS Depressant

Half-life

6-12 hours

Protein Binding

80%

Metabolized By

CYP3A4

External

Drugs.com

Boxed warning

Opioid co-use risks CNS depression/death
Dependence and withdrawal

Clinical alerts

Boxed warning

2 boxed warnings

CNS depressant

Additive sedation with other CNS depressants and alcohol

Mechanism of action

Enhances GABA-A receptor activity, producing anxiolytic/sedative effects

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Stereotypical Prolonged Seizures
·Healthy Participants
·Opioid Abuse
·Benzodiazepine Abuse
·Polysubstance Abuse

Interactions

3 curated · 3 major or contraindicated · select a row for management

Interacting drug	Severity	Effect
heroin	contraindicated	Profound respiratory depression, fatal overdose risk dramatically increased
oxycodone	contraindicated	LIFE-THREATENING respiratory depression, profound sedation, coma, and death.
rifampicin	major	Marked reduction in anxiolytic effect; risk of benzodiazepine withdrawal in chronic users.

Common adverse effects

Sedation
Dizziness
Memory impairment
Dependence

Food, alcohol & herbal

Food

Grapefruit may increase levels

Alcohol · major

Profound CNS and respiratory depression. CONTRAINDICATED.

Herbal

Kava (major) — Additive CNS depression and hepatotoxicity
Valerian (moderate) — Additive sedation

Pharmacokinetics

Half-life: 6-12 hours
Protein binding: 80%
Metabolised by: CYP3A4

Pregnancy & lactation

Not recorded for Alprazolam. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, curated interaction pairs.

Not a substitute for clinical judgement

Alprazolam Drug Profile | PharmaGraphX